1. Scrip
  2. >>Business

Leaked Data Boost J&J and Legend’s CAR-T Carvykti But Manufacturing Issues Remain

Risk Of Progression Or Death Cut By 74%

 
• By Andrew McConaghie

An accidental peek at data suggests Carvykti can outperform Bristol Myers Squibb’s rival CAR-T therapy Abecma, if it can prove a survival benefit and overcome manufacturing limitations that are hampering both products.

J&J building
The leaked data appears to confirm that Carvykti has the upperhand on BMS's rival • Source: Shutterstock

Johnson & Johnson and Legend Biotech have received an unexpectedly early boost for their CAR-T drug, Carvykti, in the shape of a leaked abstract for theh CARTITUDE-4 study showing it can cut risk of tumor progression or death by an impressive 74% compared with standard therapy.

That backs up belief that it will outperform its fellow BCMA targeting rival, Bristol Myers Squibb’s Abecma. Both products are approved in the US for use in multiple myeloma...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip